Segment Information

3 Months Ended

Mar. 31, 2014

Segment Information

Segment Information

14. Segment Information

We currently operate as one operating segment. However, our chief operating decision makers regularly review revenues, cost of revenues and gross profit data as a primary measure of performance for each of our three commercial products. We expect to measure the performance of Orenitram similarly beginning in the second quarter of 2014 with the commencement of sales.

Revenues, cost of revenues and gross profit for each of our commercial products were as follows (in thousands):

	Three Months Ended March 31,
	Remodulin		Tyvaso		Adcirca		Total
2014
Revenues	$	136,106	$	107,086	$	41,361	$	284,553
Cost of revenues	13,226		14,454		2,593		30,273
Gross profit	$	122,880	$	92,632	$	38,768	$	254,280
2013
Revenues	$	114,681	$	94,645	$	33,820	$	243,146
Cost of revenues	13,406		13,783		2,124		29,313
Gross profit	$	101,275	$	80,862	$	31,696	$	213,833

For the three-month periods ended March 31, 2014 and 2013, net revenues from our U.S.-based distributors represented 75 percent and 78 percent, respectively, of our total net operating revenues.